Prithviraj Bose, MD

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.